(American Depository Receipts)
Sinovac Biotech Ltd. (Chinese: 北京科兴生物制品有限公司, NASDAQ: SVA) is a Chinese biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. The company is based in Beijing, China. The company is listed on the NASDAQ but the exchange halted Sinovac's trading in February 2019 due to a proxy fight.
Sinovac's commercialized vaccines include Healive (hepatitis A), Bilive (combined hepatitis A and B), Anflu (influenza), Panflu (H5N1) and PANFLU.1 (H1N1). Sinovac is currently developing a Universal Pandemic Influenza vaccine and a Japanese encephalitis vaccine.[better source needed]
Sinovac is also developing vaccines for enterovirus 71 and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.
COVID-19 vaccine development
In mid-April 2020, China approved a clinical trial for a candidate COVID-19 vaccine developed by Sinovac. The vaccine, called CoronaVac, is a chemically inactivated whole virus vaccine for COVID-19. After mid-2020, CoronaVac was in Phase III clinical trials in Brazil, Chile, Indonesia, Philippines, and Turkey.
In China, CoronaVac is already being given to thousands of people under a national emergency use authorization to prevent COVID-19 infections. Instituto Butantan has said the vaccine is between 50% and 90% effective in Brazil, but withheld full results at Sinovac's request, raising questions about transparency as it was the third delay in releasing results. Separately on December 24, Turkey released Phase III results from an interim analysis of 29 cases which showed an efficacy rate of 91.25% based on the data of 1,322 participants in a trial involving 7,371 volunteers, a confusing readout compared to Brazil.
- "China's Vaccine Front-Runner Aims to Beat Covid the Old-Fashioned Way". Bloomberg. 24 August 2020.
- Dou, Eva (December 4, 2020). "As China nears a coronavirus vaccine, bribery cloud hangs over drugmaker Sinovac". The Washington Post. ISSN 0190-8286. Archived from the original on December 4, 2020. Retrieved 2020-12-06.
- Levine, Matt (May 22, 2020). "A Vaccine With a Poison Pill". Bloomberg News. Archived from the original on June 21, 2020. Retrieved December 6, 2020.
- Google Finance, url=https://www.google.com/finance?q=Sinovac
- Zhang Zhihao (15 April 2020). "Three COVID-19 vaccines approved for clinical trials". China Daily. Retrieved 23 April 2020.
- Nidhi Parekh (22 July 2020). "CoronaVac: A COVID-19 Vaccine Made From Inactivated SARS-CoV-2 Virus". Retrieved 25 July 2020.
- "New coronavirus vaccine trials start in Brazil". AP News. 21 July 2020. Retrieved 2020-10-07.
- "Chile initiates clinical study for COVID-19 vaccine". Chile Reports. 4 August 2020. Retrieved 2020-10-07.
- "248 volunteers have received Sinovac vaccine injections in Bandung". Antara News. 30 August 2020. Retrieved 2020-10-07.
- "DOH eyes 5 hospitals for Sinovac vaccine Phase 3 clinical trial". PTV News. 16 September 2020. Retrieved 2020-10-07.
- "Turkey begins phase three trials of Chinese Covid-19 vaccine". TRT World News. 1 September 2020. Retrieved 2020-10-07.
- Chang, Rachel; Iglesias, Simone (November 10, 2020). "China Vaccine Trial Halted in Brazil After Serious Adverse Event". Bloomberg News. Retrieved November 10, 2020.
- Fonseca, Pedro. "Brazil institute says CoronaVac efficacy above 50%, but delays full results". Reuters. Retrieved December 25, 2020.
- "Piecemeal data releases threaten to undermine Sinovac's COVID-19 vaccine". Reuters. 28 December 2020. Retrieved 29 December 2020.
- "Turkish official says CoronaVac vaccine 91.25% effective". ABC News. Retrieved 2020-12-26.
- "Turkey set to receive 'effective' COVID-19 vaccine amid calls for inoculation". Daily Sabah. December 25, 2020. Retrieved December 26, 2020.